Business Context and Reporting Period
SciSparc Ltd., a foreign private issuer based in Tel Aviv, Israel, filed Form 6-K for the month of June 2022. The filing primarily serves to distribute a press release dated June 2, 2022, regarding a collaboration with Clearmind Medicine Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
The material change reported is the submission of a new patent application resulting from the Company's collaboration with Clearmind Medicine Inc. The application covers a proprietary psychedelic combination intended to treat cocaine addiction.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward-Looking Statements" section from the attached press release (Exhibit 99.1). No specific financial guidance or quantitative outlook is provided within the text of this Form 6-K. The document notes that the press release is incorporated into the Company's registration statements on Form F-3 and Form S-8.
Investor Verification Checklist
- Verify the details of the patent application for the psychedelic combination to treat cocaine addiction in Exhibit 99.1.
- Review the "Forward-Looking Statements" in the press release for specific risks associated with the collaboration and drug development.
- Confirm the status of the collaboration agreement with Clearmind Medicine Inc.
- Check subsequent filings for any updates on the patent application status or financial impact of the collaboration.